Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7447619 | 0.92 | ALDH1A1 (0.60) | FYNALDH1A1CYP2D6CYP2C9ALOX15 | |
| SCHEMBL10947519 | 0.91 | FYN (0.70) | FYNCYP2D6DRD3 | |
| SCHEMBL8688816 | 0.85 | ALDH1A1 (0.69) | FYNALDH1A1CYP2D6CYP2C9ALOX15 | |
| SCHEMBL7090402 | 0.83 | FYN (0.69) | FYNALDH1A1CYP2D6CYP2C9ALOX15 | |
| SCHEMBL7093657 | 0.83 | ALDH1A1 (0.58) | FYNALDH1A1CYP2D6CYP2C9ALOX15 | |
| SCHEMBL8442018 | 0.82 | ALDH1A1 (0.57) | FYNALDH1A1CYP2D6CYP2C9ALOX15 | |
| SCHEMBL7093200 | 0.82 | ALDH1A1 (0.57) | FYNALDH1A1CYP2D6CYP2C9ALOX15 | |
| SCHEMBL7091805 | 0.82 | ALDH1A1 (0.57) | FYNALDH1A1CYP2D6CYP2C9ALOX15 | |
| SCHEMBL8443814 | 0.81 | FYN (1.00) | FYNALDH1A1CYP2D6CYP2C9ALOX15 | |
| Hydrochloric Acid SCHEMBL10878291 | 0.79 | FYN (0.67) | FYNCYP2D6DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024062395-A1 | USE OF 5-METHOXY-2-AMINOINDAN (\"MEAI\") IN METHODS FOR TREATING METABOLIC SYNDROME | Clearmind Medicine Inc. (IL) | 2024-03-28 | — | — | WO | disclosed |
| US-20230092839-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | Clearmind Medicine Inc. (CA) | 2023-03-23 | — | — | US | disclosed |
| US-11528924-B2 | Alcoholic beverage substitutes | Clearmind Medicine, Inc. (CA) | 2022-12-20 | — | — | US | disclosed |
| US-20210330609-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2021-10-28 | — | — | US | disclosed |
| US-20210330608-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2021-10-28 | — | — | US | disclosed |
| US-20210330607-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2021-10-28 | — | — | US | disclosed |
| US-11077072-B2 | Binge behavior regulators | Clearmind Medicine Inc. | 2021-08-03 | — | — | US | disclosed |
| EP-3705469-A1 | BINGE BEHAVIOR REGULATORS | GOLAN, Ezekiel (CA) | 2020-09-09 | — | — | EP | disclosed |
| EP-3230255-B1 | BINGE BEHAVIOR REGULATORS | GOLAN EZEKIEL (CA) | 2020-03-18 | — | — | EP | disclosed |
| EP-3230256-B1 | ALCOHOLIC BEVERAGE SUBSTITUTES | GOLAN EZEKIEL (CA) | 2019-11-13 | — | — | EP | disclosed |
| WO-2016092547-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | GOLAN EZEKIEL (IL) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092546-A1 | BINGE BEHAVIOR REGULATORS | GOLAN EZEKIEL (IL) | 2016-06-16 | — | — | WO | disclosed |
| EP-0923542-B1 | ARYL SUBSTITUTED CYCLIC AMINES AS SELECTIVE DOPAMINE D3 LIGANDS | UPJOHN CO (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6084130-A | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0712387-B1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | UPJOHN CO (US) | 1999-12-08 | — | — | EP | disclosed |
| EP-0923542-A1 | ARYL SUBSTITUTED CYCLIC AMINES AS SELECTIVE DOPAMINE D3 LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5708018-A | 2-aminoindans as selective dopamine D3 ligands | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| WO-1997045403-A1 | ARYL SUBSTITUTED CYCLIC AMINES AS SELECTIVE DOPAMINE D3 LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-04 | — | — | WO | disclosed |
| EP-0712387-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995004713-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | THE UPJOHN COMPANY (US) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092839-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | ADH1A, ADH5, ADH1C | FYN 3559/4885ALDH1A1 34/4885CYP2D6 1235/4885 |
| US-11077072-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | FYN 4855/4885ALDH1A1 847/4885CYP2D6 2059/4885 |
| US-20210330609-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | FYN 4855/4885ALDH1A1 847/4885CYP2D6 2059/4885 |
| US-11528924-B2 | Alcoholic beverage substitutes | ADH1A, ADH5, ADH1C | FYN 3559/4885ALDH1A1 34/4885CYP2D6 1235/4885 |
| US-20210330607-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | FYN 4855/4885ALDH1A1 847/4885CYP2D6 2059/4885 |
| US-20210330608-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | FYN 4855/4885ALDH1A1 847/4885CYP2D6 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.